What is Retatrutide?
Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) is a 39-amino acid triple-receptor peptide. Triple receptor co-agonist simultaneously activating GLP-1R, GIPR, and GCGR. GCGR activation adds thermogenesis, fatty acid oxidation, and hepatic glucose production modulation beyond dual GIP+GLP-1 agonism. Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks (12mg dose).
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized |
| Molecular Formula | Large synthetic peptide (sequence-specific; proprietary) |
| Peptide Type | Triple Receptor Agonist (GLP-1 / GIP / Glucagon Receptors) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | USA |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | As indicated by manufacturer |
Research Use Disclaimer
All OSR products are strictly for laboratory, scientific, and research use only. They are not for human consumption, medical treatment, diagnosis, or disease prevention.
By purchasing or using OSR products, you confirm:
- You are a qualified researcher or acting under the supervision of one.
- Products will only be used for legitimate research purposes.
- Products are not evaluated by the FDA or any regulatory authority for human use.
- You assume all responsibility for legal compliance, proper handling, and storage.
- You meet the legal age requirement in your jurisdiction.
No Warranty: Products are sold “as is,” with no express or implied warranties regarding efficacy, safety, or suitability. Results in research may vary. OSR is not responsible for outcomes, interpretations, or conclusions drawn from any studies conducted using these products.
